Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity.
Kapoor P et al. Nat Rev Clin Oncol. 2017 Feb;14(2):73-74. doi: 10.1038/nrclinonc.2016.221. Epub 2017 Jan 10.

Trends in overall survival and costs of multiple myeloma, 2000-2014.
Fonseca R et al. Leukemia. 2017 Jan 20. doi: 10.1038/leu.2016.380. [Epub ahead of print].

Current treatment options of T cell-associated immunotherapy in multiple myeloma.
Liu H et al. Clin Exp Med. 2017 Jan 24. doi: 10.1007/s10238-017-0450-9. [Epub ahead of print].

Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Gavriatopoulou M et al. Expert Opin Drug Saf. 2017 Feb;16(2):237-245. doi: 10.1080/14740338.2017.1279603. Epub 2017 Jan 11.

Trends and Patterns of Disparities in Cancer Mortality Among US Counties, 1980-2014.
Mokdad AH et al. JAMA. 2017 Jan 24;317(4):388-406. doi: 10.1001/jama.2016.20324.

Proteasome inhibitors in cancer therapy.
Manasanch EE et al. Nat Rev Clin Oncol. 2017 Jan 24. doi: 10.1038/nrclinonc.2016.206. [Epub ahead of print].

Deacetylase Inhibitors: an Advance in Myeloma Therapy?
Laubach JP et al. Expert Rev Hematol. 2017 Jan 11. doi: 10.1080/17474086.2017.1280388. [Epub ahead of print].

Pomalidomide in multiple myeloma.
Uccello G et al. Expert Opin Pharmacother. 2016 Dec 26:1-5. doi: 10.1080/14656566.2016.1274973. [Epub ahead of print].

Safety issues and managment of toxicities associated with new treatments for multiple myeloma.
Brioli A et al. Expert Rev Hematol. 2017 Jan 24. doi: 10.1080/17474086.2017.1284584. [Epub ahead of print].

Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Boudreault JS et al. Expert Rev Hematol. 2017 Jan 21. doi: 10.1080/17474086.2017.1285694. [Epub ahead of print].

Could daratumumab be used to treat severe allergy?
Blankestijn MA et al. J Allergy Clin Immunol. 2017 Jan 18. pii: S0091-6749(17)30042-8. doi: 10.1016/j.jaci.2016.12.955. [Epub ahead of print].

Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union.
Polsinelli B et al. Orphanet J Rare Dis. 2017 Jan 21;12(1):17. doi: 10.1186/s13023-017-0567-7.

Pediatric multiple myeloma.
Pilbeam KL et al. Blood. 2017 Jan 19;129(3):395. doi: 10.1182/blood-2016-09-741322.

Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.
Mondello P et al. Oncotarget. 2017 Jan 12. doi: 10.18632/oncotarget.14610. [Epub ahead of print].

Understanding the Relationship Between Care Volume and Clinical Outcomes in Multiple Myeloma.
Halm EA et al. J Clin Oncol. 2017 Jan 17:JCO2016704726. doi: 10.1200/JCO.2016.70.4726. [Epub ahead of print].

Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China.
Zhong YP et al. Chin Med J (Engl). 2017 20th Jan;130(2):130-134. doi: 10.4103/0366-6999.197977.

Is immunotherapy here to stay in multiple myeloma?
Rodriguez-Otero P et al. Haematologica. 2017 Jan 12. pii: haematol.2016.152504. doi: 10.3324/haematol.2016.152504. [Epub ahead of print].

Return to the Primary Acute Care Service Among Patients With Multiple Myeloma on an Acute Inpatient Rehabilitation Unit.
Fu JB et al. PM R. 2017 Jan 8. pii: S1934-1482(17)30021-7. doi: 10.1016/j.pmrj.2016.12.007. [Epub ahead of print].

Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
Shank BR et al. Pharmacotherapy. 2017 Jan 12. doi: 10.1002/phar.1900. [Epub ahead of print].

Discovery of Natural Product Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives.
Wang H et al. Curr Protein Pept Sci. 2017 Jan 11. [Epub ahead of print].

Cancer incidence in cohorts of workers in the rubber manufacturing industry first employed since 1975 in the UK and Sweden.
Boniol M et al. Occup Environ Med. 2017 Jan 6. pii: oemed-2016-103989. doi: 10.1136/oemed-2016-103989. [Epub ahead of print].

Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.
Liu X et al. Onco Targets Ther. 2016 Dec 22;10:121-128. doi: 10.2147/OTT.S123680. eCollection 2017.

Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.
Chang SH et al. J Natl Cancer Inst. 2016 Dec 31;109(5). pii: djw264. doi: 10.1093/jnci/djw264. Print 2017 May.

Further psychometric validation of the GAH scale: Responsiveness and effect size.
Cruz-Jentoft AJ et al. J Geriatr Oncol. 2016 Dec 22. pii: S1879-4068(16)30173-4. doi: 10.1016/j.jgo.2016.12.008. [Epub ahead of print].